Unlocking the full potential of personalized medicine through multiplexed RNA-based technologies

Cancer is often viewed as one monolithic disease, but in fact every cancer is unique.

The incidence and mortality rates for cancer continue to rise according to the latest figures from the U.S. National Cancer Institute. Personalized medicine shows considerable promise when it comes to cancer treatment, but for it to reach its potential, the diagnostic methods must be up to the challenge.

Dr. Pavol Cekan, co-founder and CEO of the RNA-based diagnostics development startup MultiplexDX, believes that RNA holds the secret of accurate, reliable and affordable diagnostics.

In this exclusive interview, Dr. Cekan discusses his research, including the development of diagnostic techniques based on RNA fluorescence in situ hybridization and sequencing and capable of reliably discriminating between similar cancer types.

Read the interview to discover:

  • How current diagnostic techniques fall short of supporting personalized medicine
  • The development potential of this new technology
  • How RNA-based technology could also support drug response monitoring and testing in clinical trials

Read the interview now.

To access the complimentary interview 'Unlocking the full potential of personalized medicine through multiplexed RNA-based technologies', please fill in the form below.